Los Angeles Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29M Sell
64,937
-228,364
-78% -$106M 0.11% 156
2025
Q4
$123M Buy
293,301
+257,829
+727% +$111M 0.42% 48
2025
Q3
$13.9M Buy
35,472
+2,458
+7% +$1.03M 0.05% 236
2025
Q2
$14.7M Buy
33,014
+7,291
+28% +$3.36M 0.06% 204
2025
Q1
$12.5M Buy
25,723
+24,421
+1,876% +$11.4M 0.06% 206
2024
Q4
$524K Sell
1,302
-17,425
-93% -$8.08M ﹤0.01% 802
2024
Q3
$8.71M Sell
18,727
-45,969
-71% -$22.1M 0.04% 266
2024
Q2
$30.3M Sell
64,696
-68,018
-51% -$29.5M 0.11% 146
2024
Q1
$55.5M Sell
132,714
-257,160
-66% -$109M 0.19% 112
2023
Q4
$159M Sell
389,874
-37,196
-9% -$13.7M 0.59% 33
2023
Q3
$149M Buy
427,070
+842
+0.2% +$294K 0.63% 33
2023
Q2
$150M Sell
426,228
-30,927
-7% -$10.4M 0.6% 34
2023
Q1
$144M Buy
457,155
+10,144
+2% +$3.04M 0.64% 37
2022
Q4
$129M Buy
447,011
+12,485
+3% +$3.81M 0.63% 41
2022
Q3
$126M Buy
434,526
+97,060
+29% +$27.9M 0.65% 35
2022
Q2
$95.1M Sell
337,466
-17,352
-5% -$4.64M 0.47% 47
2022
Q1
$92.6M Buy
354,818
+52,813
+17% +$12.5M 0.36% 63
2021
Q4
$66.3M Buy
302,005
+147,876
+96% +$28.8M 0.25% 92
2021
Q3
$28M Sell
154,129
-15,228
-9% -$2.97M 0.13% 144
2021
Q2
$34.1M Sell
169,357
-55,063
-25% -$11.5M 0.15% 139
2021
Q1
$48.2M Sell
224,420
-82,644
-27% -$18.2M 0.22% 107
2020
Q4
$72.6M Sell
307,064
-9,251
-3% -$2.12M 0.31% 68
2020
Q3
$86.1M Sell
316,315
-16,597
-5% -$4.58M 0.4% 56
2020
Q2
$96.6M Buy
332,912
+22,412
+7% +$6.08M 0.47% 44
2020
Q1
$73.9M Buy
310,500
+4,390
+1% +$1.01M 0.47% 55
2019
Q4
$67M Sell
306,110
-77,453
-20% -$15.7M 0.33% 81
2019
Q3
$65M Sell
383,563
-50,423
-12% -$8.92M 0.35% 76
2019
Q2
$79.6M Sell
433,986
-1,000
-0.2% -$175K 0.43% 59
2019
Q1
$80M Sell
434,986
-7,000
-2% -$1.29M 0.44% 52
2018
Q4
$73.2M Sell
441,986
-98,831
-18% -$17.1M 0.45% 56
2018
Q3
$104M Buy
540,817
+1,659
+0.3% +$295K 0.55% 30
2018
Q2
$91.6M Buy
539,158
+222,318
+70% +$34.5M 0.51% 31
2018
Q1
$51.6M Sell
316,840
-2,680
-0.8% -$438K 0.29% 91
2017
Q4
$47.9M Buy
319,520
+234,181
+274% +$34.7M 0.26% 96
2017
Q3
$13M Buy
85,339
+81,727
+2,263% +$12.3M 0.07% 271
2017
Q2
$465K Buy
+3,612
New +$435K ﹤0.01% 957
2017
Q1
Sell
-23,268
Closed -$1.71M 1219
2016
Q4
$1.71M Sell
23,268
-154,012
-87% -$12.5M 0.01% 575
2016
Q3
$15.5M Sell
177,280
-11,821
-6% -$1.12M 0.13% 217
2016
Q2
$16.3M Buy
+189,101
New +$16.3M 0.14% 190
2016
Q1
Sell
-2,114
Closed -$266K 1199
2015
Q4
$266K Sell
2,114
-2,322
-52% -$280K ﹤0.01% 1009
2015
Q3
$462K Sell
4,436
-325,129
-99% -$41.8M ﹤0.01% 899
2015
Q2
$40.7M Buy
329,565
+17,250
+6% +$2.17M 0.38% 73
2015
Q1
$36.8M Buy
312,315
+309,801
+12,323% +$37.1M 0.34% 89
2014
Q4
$299K Hold
2,514
﹤0.01% 971
2014
Q3
$282K Hold
2,514
﹤0.01% 937
2014
Q2
$238K Sell
2,514
-80,230
-97% -$5.63M ﹤0.01% 1097
2014
Q1
$5.85M Sell
82,744
-31,110
-27% -$2.46M 0.06% 319
2013
Q4
$8.46M Sell
113,854
-54,252
-32% -$3.78M 0.09% 255
2013
Q3
$12.7M Buy
168,106
+157,393
+1,469% +$12.5M 0.16% 191
2013
Q2
$858K Buy
+10,713
New +$789K 0.01% 712

Other funds holding VRTX

Los Angeles Capital Management's VRTX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 78% in Q1 2026, selling an estimated $106M and leaving 64,937 shares worth $29M. The position accounts for 0.11% of the portfolio, ranked #156.

Los Angeles Capital Management first reported a position in VRTX in Q2 2013 and has held it in 50 quarters since. The position peaked at $159M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Los Angeles Capital Management held 64,937 shares of Vertex Pharmaceuticals worth $29M as of Q1 2026.
  • Los Angeles Capital Management sold 228,364 Vertex Pharmaceuticals shares in Q1 2026, an estimated $106M.
  • Vertex Pharmaceuticals made up 0.11% of Los Angeles Capital Management's portfolio in Q1 2026, its #156 holding.
  • Los Angeles Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Los Angeles Capital Management's Vertex Pharmaceuticals position peaked at $159M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.